# hepatocellular carcinoma (HCC) - glm-5.2

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: liver tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Zhipu AI / glm-5.2
- Message SHA-256: be503ca72a7bcd2f0eb88c8049c4935f5ef704fb40bd5170c65ca64b33a1d716
- Response HTTP status: 200
- Prompt tokens: 26631
- Completion tokens: 7898
- Reasoning tokens: 0
- Total tokens: 34529
- API requests reported: 3
- Elapsed seconds: 252.481
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1376.986
- Question handoff seconds: 1390.502
- Final benchmark system: E2seq; file rank 4/5; original repeat 5; model vendor: Zhipu AI

---
# HCC Prognosis Cohort Interpretation

## Data-Quality Warning

The uploaded HR values are **technically degenerate and non-interpretable as statistical evidence**. Approximately 80% of genes share an identical HR of 5.185×10²¹ with P=0 and FDR=0; the three "protective" genes share an identical HR of 1.929×10⁻²². These values indicate **complete Cox model separation or numerical overflow**, not biological signal. No meaningful gene-level risk ranking can be derived from these numbers. The analysis below is therefore **exploratory only**, grounded in external annotations and literature, with direct statistical evidence labeled as unreliable.

---

## 1. Overall Biological Interpretation

The selected cohort is dominated by **non-coding RNAs (ncRNAs), pseudogenes, and olfactory receptor (OR) genes** — categories not typically central to HCC biology. The few protein-coding genes with functional annotations (CRH, IRS4, FOXI1, FOXR2, SLC1A6, OTX2) point toward **neuroendocrine signaling, developmental transcription factor reactivation, and glutamate/aspartate transport** as potential — though weakly supported — thematic signals. The overwhelming representation of pseudogenes and unannotated lncRNAs suggests the model may have captured **technical noise or extreme sparsity artifacts** rather than a coherent HCC prognostic program.

**External statistical validation was not performed.**

---

## 2. Core Biological Programs

### Program 1: Non-coding RNA Regulatory Landscape
- **Prognostic association:** Risk-associated (97 genes HR>1, all unreliable)
- **Representative genes:** MIR182, Y_RNA, multiple RNU/RN7SK pseudogenes, LINC series
- **Pathway:** No standardized pathway; literature links Y-RNAs to cancer biomarkers (PMID: 32423154) and MIR182 to tumor progression (PMID: 22790015)
- **Rationale:** ncRNAs constitute >60% of the cohort. MIR182 has established oncogenic roles in multiple cancers; Y-RNAs are emerging EV-associated biomarkers.
- **Evidence strength:** Weak — no direct statistical reliability; literature is disease-non-specific. **Limitation:** These ncRNAs may reflect expression artifacts from low-count regions.

### Program 2: Olfactory Receptor / Chemosensory Signaling
- **Prognostic association:** Risk-associated
- **Representative genes:** OR2M7, OR5M10, OR5T2, OR5M5P, OR5M13P
- **Pathway:** GO:0007186 (G protein-coupled receptor signaling); KEGG: olfactory transduction
- **Rationale:** Multiple OR genes cluster via STRING to ARRB1/ARRB2/GNAL/GNB1/GNG13 — canonical GPCR signaling components. OR ectopic expression is documented in various carcinomas.
- **Evidence strength:** Moderate pathway coherence; **no HCC-specific OR prognostic literature** identified. **Limitation:** Most are pseudogenes (OR5M5P, OR5M13P); signal likely reflects genomic amplification artifacts.

### Program 3: Neuroendocrine / Developmental Reactivation
- **Prognostic association:** Risk-associated
- **Representative genes:** CRH, OTX2, FOXI1, FOXR2
- **Pathway:** No unified standardized pathway; Reactome maps to generic transcription regulation
- **Rationale:** CRH (corticotropin-releasing hormone) and OTX2 (developmental TF) suggest aberrant reactivation of embryonic/neuroendocrine programs. FOXI1 and FOXR2 are forkhead TFs with developmental roles.
- **Evidence strength:** Exploratory — no direct HCC prognostic literature for these specific genes. **Limitation:** Single-gene annotations without multi-gene pathway convergence.

### Program 4: Insulin Signaling / Metabolic Regulation
- **Prognostic association:** Risk-associated
- **Representative genes:** IRS4, SLC1A6, CRH
- **Pathway:** KEGG: Type II diabetes mellitus; GO:0070092 (regulation of glucagon secretion)
- **Rationale:** IRS4 is an insulin receptor substrate; SLC1A6 is a glutamate/aspartate transporter linked to metabolic signaling. HCC arises in metabolic disease contexts (NAFLD, diabetes).
- **Evidence strength:** Weak — only two coding genes; pathway enrichment may derive from SLC1A6 alone. **Limitation:** SLC1A6 expression is primarily cerebellar (GTEx); liver expression is negligible, suggesting this signal is unlikely to reflect true hepatic biology.

### Program 5: Pseudogene / Processed Transcript Aggregation
- **Prognostic association:** Risk-associated (majority)
- **Representative genes:** S100A7P1, SNAI1P1, PLA2G10P1, ALDH7A1P3, NF1P7, YWHAZP8, RPL5P21
- **Pathway:** None applicable
- **Rationale:** ~30% of the cohort are pseudogenes. SNAI1P1 (SNAIL pseudogene) is notable given SNAIL's role in HCC EMT, but pseudogene expression is often a mapping artifact.
- **Evidence strength:** Insufficient for biological inference. **Limitation:** Pseudogene reads may reflect multi-mapping from parent genes or repetitive element contamination.

---

## 3. Key Genes and Interaction Modules

| Gene/Module | Prognostic Direction | Potential Role | Relationship Type | Evidence |
|---|---|---|---|---|
| **MIR182** | Risk (HR unreliable) | Oncogenic miR; targets in HCC EMT/invasion | Regulatory (miRNA-target) | Literature (PMID: 22790015); no HCC-specific record retrieved |
| **IRS4** | Risk (HR unreliable) | Insulin/metabolic signaling in HCC context | Pathway co-membership (KEGG Type II diabetes) | Direct annotation; GTEx shows low liver expression |
| **SLC1A6** | Risk (HR unreliable) | Aspartate/glutamate transport | Pathway co-membership; STRING link to KAT5 | GTEx: cerebellum-dominant, minimal liver expression |
| **CRH** | Risk (HR unreliable) | Neuroendocrine stress signaling | Pathway co-membership (glucagon regulation) | Annotation only; no HCC prognostic literature |
| **OR module (OR2M7/OR5M10/OR5T2)** | Risk (HR unreliable) | Ectopic GPCR signaling | Pathway co-membership (GO:0007186); STRING network with ARRB1/2, GNAL, GNB1, GNG13 | STRING network evidence; no HCC-specific support |
| **FOXR2** | Risk (HR unreliable) | Developmental TF reactivation | STRING link to KAT5 | Annotation only |
| **Y_RNA** | Risk (HR unreliable; 168 conflicting rows) | EV-associated biomarker candidate | Co-expression (putative) | Literature (PMID: 32423154, 32944168); direction conflict flag |
| **CENPVL3** | Protective (HR unreliable) | Centromere-associated protein | None identified | Annotation only; protective direction not trustworthy |
| **OTX2** | Risk (HR unreliable) | Developmental TF | None identified | No HCC-specific record |
| **SNAI1P1** | Risk (HR unreliable) | Pseudogene of SNAI1 (EMT regulator) | Indirect/putative link to SNAI1 | No direct interaction evidence |

**Interaction type distinctions:** STRING links between OR genes and GPCR pathway members (ARRB1/2, GNAL, GNB1, GNG13) represent **predicted/curated protein associations**, not direct physical interaction validated in HCC. The KAT5–FOXR2/SLC1A6 STRING links are **database-predicted** and have no HCC experimental support. No direct physical interaction has been demonstrated for any pair within this cohort in HCC tissue.

---

## 4. Validation Priorities

### Priority 1: Cox Model Separation Diagnosis (Confounding/Composition Check)
- **Why:** Degenerate HRs render all prognostic claims invalid; must determine if this reflects extreme sparsity, perfect separation, or coding errors.
- **Current evidence:** 80% identical HR values; P=0 and FDR=0 across all genes — mathematically impossible under normal Cox conditions.
- **Next step:** Re-fit Cox models with penalization (Firth correction) or exclude genes with <10% non-zero expression; examine variance and event distribution per gene.
- **Status:** **Established evidence** that the current statistics are unusable.

### Priority 2: MIR182 in HCC Prognosis (Biomarker)
- **Why:** MIR182 is the only gene with established oncogenic roles in epithelial cancers and plausible HCC relevance.
- **Current evidence:** Unreliable HR; literature supports oncogenic function in ovarian cancer (PMID: 22790015) and inflammatory regulation (PMID: 31908034).
- **Next step:** Validate MIR182 expression and OS association in TCGA-LIHC or an independent HCC cohort using standard Cox regression.
- **Status:** **Exploratory hypothesis.**

### Priority 3: IRS4 / Metabolic Signaling Axis (Mechanistic Hypothesis)
- **Why:** IRS4 connects to insulin/TGF-β signaling; HCC is metabolically driven.
- **Current evidence:** Unreliable HR; KEGG Type II diabetes pathway mapping; GTEx shows IRS4 has low but detectable liver expression.
- **Next step:** Assess IRS4 protein expression in HCC vs. normal liver by IHC; test correlation with metabolic syndrome-associated HCC subtypes.
- **Status:** **Exploratory hypothesis.**

### Priority 4: Ectopic OR Gene Expression in HCC (Interaction/Network Hypothesis)
- **Why:** OR gene clustering with GPCR pathway members is pathway-coherent but HCC-unvalidated.
- **Current evidence:** STRING network (ARRB1/2, GNAL, GNB1, GNG13); GO:0007186 enrichment; no HCC literature support.
- **Next step:** Confirm OR2M7/OR5M10/OR5T2 expression in HCC RNA-seq datasets; test whether OR expression correlates with tumor grade or differentiation.
- **Status:** **Exploratory hypothesis.**

### Priority 5: Y-RNA as EV-Associated HCC Biomarker (Biomarker)
- **Why:** Y-RNAs in extracellular vesicles are emerging cancer biomarkers (PMID: 32423154, 32944168); Y_RNA showed direction-conflict flags.
- **Current evidence:** Unreliable HR; 168 conflicting rows in ledger; literature is non-HCC-specific.
- **Next step:** Quantify Y-RNA subtypes in HCC patient plasma EVs vs. cirrhotic controls; assess subtype ratio stability.
- **Status:** **Exploratory hypothesis.**

---

## 5. Evidence Grounding Summary

| Claim | Direct Evidence | Pathway/Ontology | Network | Disease/Literature | Tissue/Expression |
|---|---|---|---|---|---|
| Cox statistics unusable | ✅ Uploaded values | — | — | — | — |
| ncRNA dominance | ✅ Gene list composition | — | — | Partial (PMID: 32423154) | — |
| OR/GPCR signaling | ❌ HR unreliable | ✅ GO:0007186 | ✅ STRING (ARRB1/2, GNAL) | ❌ No HCC records | GTEx: OR genes minimal in liver |
| Metabolic/insulin axis | ❌ HR unreliable | ✅ KEGG Type II DM | — | ❌ No HCC records for IRS4 | GTEx: IRS4 low liver; SLC1A6 cerebellum-dominant |
| MIR182 oncogenic role | ❌ HR unreliable | — | — | ✅ Non-HCC literature | — |

**Independence assessment:** STRING and GO/KEGG annotations for OR genes likely derive from the same underlying GPCR pathway annotations — they are **not independent**. Literature records for MIR182 and Y-RNA are from different cancer types and are **independent of each other** but **non-specific to HCC**.

**Conflicting evidence:** SLC1A6 is mapped to liver-relevant metabolic pathways (KEGG Type II diabetes) but GTEx expression data show it is essentially cerebellum-specific, creating a **tissue-plausibility conflict** that undermines its interpretation as an HCC prognostic gene.

---

## 6. Limitations and Alternative Explanations

1. **Complete Cox model failure:** The identical extreme HRs and universal P=0 indicate numerical separation, likely from genes expressed in very few samples perfectly predicting event status. This is the dominant limitation and invalidates all direct statistical inference. **Investigation:** Apply Firth penalized Cox or bootstrap correction; examine per-gene event stratification tables.

2. **Tissue-composition confounding:** Many selected genes (OR genes, CRH, FOXI1, SLC1A6) are not physiologically expressed in liver. Their detection may reflect **contaminating tissue, rare cell populations, or read-mapping artifacts** from repetitive/paralogous sequences. **Investigation:** Compare expression levels to GTEx liver median; perform cell-type deconvolution.

3. **Pseudogene and ncRNA mapping artifacts:** ~30% pseudogenes and numerous RNU/RN7SK/RNA5SP entries suggest **multi-mapping from repetitive genomic regions**. These reads may not represent genuine transcriptional signal. **Investigation:** Re-align with unique-mapping filters; assess multi-map rate per gene.

4. **Direction-conflict flags:** Y_RNA had 168 conflicting rows, suggesting **inconsistent probe-to-gene mapping or multiple genomic loci** with opposite expression patterns. **Investigation:** Resolve genomic coordinates; collapse or exclude ambiguous probes.

5. **Association-versus-causation:** Even if statistics were valid, Cox HRs in bulk tumor transcriptomics reflect **confounded associations** with tumor stage, purity, and treatment — not causal gene effects. No independent cohort replication is available. **Investigation:** Validate in TCGA-LIHC with adjusted models including stage, etiology, and treatment covariates.

---

**Summary:** The uploaded cohort statistics are degenerate and cannot support reliable prognostic inference. Exploratory annotation-based analysis identifies non-coding RNA biology, ectopic olfactory receptor/GPCR signaling, and metabolic pathway hints as the most coherent — though weakly supported — themes. The highest immediate priority is not biological validation but **statistical re-analysis with appropriate model corrections** to determine whether any genuine prognostic signal exists beneath the numerical artifacts.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=0, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Zhipu AI / glm-5.2

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 56/100 selected items (partially returned; some queries failed); cbioportal 57/100 selected items (records returned); chembl 5/100 selected items (partially returned; some queries failed); civic 1/100 selected items (records returned); clinicaltrials 5/100 selected items (records returned); clinvar 29/100 selected items (records returned); ensembl 19/100 selected items (partially returned; some queries failed); europepmc 305 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 78/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 61/100 selected items (records returned); intact 10/100 selected items (partially returned; some queries failed); mygene 65/100 selected items (records returned); omnipath 6/100 selected items (records returned); opentargets 54/100 selected items (partially returned; some queries failed); pubmed 100 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 14/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 15/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 1/100 selected items (records returned); string 15/100 selected items (records returned); trrust 3/100 selected items (records returned)
